Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to euro12000-64000 according to cost-per-QALY thresholds of euro38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.
Hjelmgren
Jonas
J
The Swedish Institute for Health Economics, P.O. Box 2127, SE-220 02 Lund, Sweden.
Ghatnekar
Ola
O
Reimer
Jan
J
Grabowski
Martin
M
Lindvall
Olle
O
Persson
Ulf
U
Hagell
Peter
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis; D003657:Decision Making; D018450:Disease Progression; D004298:Dopamine / Q000502:physiology; D015316:Genetic Therapy / Q000191:economics*; D006801:Humans; D008875:Middle Aged; D017059:Models, Econometric; D009474:Neurons / Q000502:physiology / Q000637:transplantation; D010300:Parkinson Disease / Q000191:economics* / Q000601:surgery / Q000628:therapy*; D011788:Quality of Life; D012680:Sensitivity and Specificity; D033581:Stem Cell Transplantation / Q000191:economics*
D004298:Dopamine